Roche

(IN BRIEF) Roche has received FDA acceptance under Priority Review for its New Drug Application for giredestrant as an adjuvant treatment for adults with ER-positive, HER2-negative stage I-III breast cancer. The FDA is expected to decide on the application by … Read the full press release →

(IN BRIEF) Roche has agreed to acquire PathAI to strengthen its digital pathology and AI-powered diagnostics capabilities. The deal builds on an existing partnership between the companies focused on AI-enabled companion diagnostics and pathology solutions. Roche said the acquisition will … Read the full press release →

(IN BRIEF) Roche has reached a key regulatory milestone with the FDA’s acceptance of its application for Gazyva/Gazyvaro as a treatment for systemic lupus erythematosus. The submission is based on strong phase III trial data showing significant improvements in disease … Read the full press release →

(IN BRIEF) Roche has obtained CE mark approval for its Elecsys Neurofilament Light Chain blood test, which detects neuroinflammation in patients with relapsing-remitting multiple sclerosis. The minimally invasive test measures biomarkers of nerve damage, offering an alternative to traditional monitoring … Read the full press release →

(IN BRIEF) New data presented at EHRA 2026 show that individuals with atrial fibrillation detected through screening face a threefold higher risk of developing heart failure compared with those without AF, with a risk level similar to patients with known … Read the full press release →

(IN BRIEF) Roche has launched the cobas MPX-E assay, a multiplex molecular diagnostic test capable of detecting HIV, Hepatitis B, Hepatitis C, and Hepatitis E simultaneously in a single workflow. Available in CE mark–accepting markets, the assay is designed to … Read the full press release →